Yuko Mishima

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Mats Jerkeman et al. · New England Journal of Medicine · 2022 · 196 citations · Full text

Ricolinostat (<scp>ACY</scp>‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

Yuko Mishima, Loredana Santo, Homare Eda et al. · British Journal of Haematology · 2015 · 99 citations

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Daisuke Ennishi, Kengo Takeuchi, Masaru Yokoyama et al. · Annals of Oncology · 2008 · 99 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +11

BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation

Naoko Tsuyama, Seiji Sakata, Satoko Baba et al. · Blood · 2017 · 86 citations · Full text

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma

Yasuhito Terui, Yuji Mishima, Natsuhiko Sugimura et al. · Clinical Cancer Research · 2009 · 72 citations · Full text